Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. is a US-based oncology-focused RNAi nanoparticle drug development company. It specializes in developing products based on DNAbilize, a drug delivery and antisense technology using P-ethoxy, a DNA backbone modification. The company's revenue is generated through the development and potential commercialization of its lead drug candidate, prexigebersen, currently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, it is working on Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia, Liposomal STAT3 for pancreatic cancer, non-small cell lung cancer, and AML, and prexigebersen-A for various solid tumors.

Products

• Prexigebersen (Phase II clinical trials)

• Liposomal Bcl-2

• Liposomal STAT3

• Prexigebersen-A